Senzime Strengthens Position in Pediatric Anesthesia by Securing Another Hospital Contract and Highlighting Positive Outcome Data

Rhea-AI Summary

Senzime (OTCQX:SNZZF) reported progress in pediatric anesthesia, winning a new contract from a top-ranked pediatric hospital in the Eastern U.S. to equip all operating rooms with TetraGraph systems after competitive evaluation.

New pediatric research shows reduced respiratory complications and cost savings with quantitative neuromuscular monitoring.

Positive

• New Eastern U.S. pediatric hospital contract to equip all ORs with TetraGraph
• Competitive evaluation resulted in TetraGraph selection for hospital-wide pediatric use
• Pediatric study shows reduced postoperative respiratory complications with quantitative monitoring
• Study indicates cost savings for pediatric anesthesia when monitoring is used versus no monitoring
• TetraGraph pediatric solution has dedicated FDA 510(k) clearance
• Senzime reports several recent pediatric contracts across the U.S. and Europe

Negative

• None.

News Market Reaction – SNZZF

-7.19%

-7.19% Session close to close

In the Jun 3 session, SNZZF declined 7.19%, reflecting a notable negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

UPPSALA, SE / ACCESS Newswire / June 3, 2026 / Senzime AB (STO:SEZI)(OTCQX:SNZZF) announced today advancements within pediatric anesthesia, securing another top ranked pediatric hospital contract. The pediatric hospital, based in the Eastern U.S., awarded the contract to Senzime to equip all operating rooms with TetraGraph systems following a competitive evaluation. In addition, new presented research demonstrates positive outcomes and cost benefits of quantitative neuromuscular monitoring in pediatrics.

Pediatric anesthesia is considered one of the more specialized and demanding areas of anesthesia, with the use of paralytic drugs and neuromuscular monitoring not yet as widespread as in adult care. Major studies have shown that as few as 16% of children receiving neuromuscular blocking drugs are adequately monitored, and the absence of monitoring has been directly linked to higher rates of postoperative respiratory complications. Following recent pediatric guidelines related to neuromuscular blocking drugs and monitoring, as well as recent U.S. market approval for the use of paralytic reversal drugs in infants, awareness around perioperative neuromuscular monitoring has increased significantly.

In a recent study (Morris B. et al., 2026) conducted at Children's Hospital Colorado, researchers showed that quantitative neuromuscular monitoring not only led to a reduction in respiratory complications, but also cost savings compared to no monitoring, confirming monitoring as a dominant high value strategy in pediatric anesthesia. The award-winning study was presented at the IARS 2026 Congress in Montreal, Canada.

"We are accelerating the adoption of our technology within pediatric hospitals, with several important contracts recently secured across the U.S. and Europe. Our pediatric monitoring solution is not simply a derivative of an adult product, but is specifically designed with proprietary soft materials for use on the most sensitive patients, and it has its own FDA 510(k) clearance," commented Philip Siberg, CEO of Senzime. "In addition, TetraGraph is supported by strong clinical and health economic data that further justifies investments in patient safety."

For further information, please contact:

Philip Siberg, CEO of Senzime AB
Phone: +46 (0) 707 90 67 34, e-mail: philip.siberg@senzime.com

About Senzime

Senzime is a leading medical device company at the forefront of a changing healthcare market, driven by new clinical guidelines and emerging technologies. Established in 1999, Senzime develops and markets precision-based monitoring systems that improve outcomes, reduce costs, and advance perioperative patient safety. The flagship solution is the TetraGraph® system, proven best-in-class for accurate monitoring of neuromuscular transmission during surgery and used in thousands of operating rooms across the globe. The system helps to secure precise dosing of paralytic drugs and provides enhanced insights to safeguard every patient's journey, from anesthesia to recovery.

Headquartered in Uppsala, Sweden, Senzime is publicly traded on the Nasdaq Stockholm Main Market (SEZI), with cross-trading on the US OTCQX Market (SNZZF), and backed by long-term investors. More information is available at senzime.com.

Attachments

Senzime strengthens position in pediatric anesthesia by securing another hospital contract and highlighting positive outcome data

SOURCE: Senzime

View the original press release on ACCESS Newswire

FAQ

What pediatric anesthesia contract did Senzime (OTCQX:SNZZF) announce on June 3, 2026?

Senzime announced a new contract with a top-ranked pediatric hospital in the Eastern U.S. to equip all operating rooms with TetraGraph systems. According to Senzime, the contract followed a competitive evaluation against alternative neuromuscular monitoring solutions.

How does Senzime's TetraGraph benefit pediatric anesthesia patients?

TetraGraph provides quantitative neuromuscular monitoring for children, supporting safer use of paralytic drugs. According to Senzime, monitoring has been linked to reduced postoperative respiratory complications and aligns with recent pediatric guidelines on neuromuscular blocking drugs and perioperative monitoring.

What did the 2026 Children's Hospital Colorado study show about pediatric neuromuscular monitoring?

The Morris B. et al. 2026 study showed that quantitative neuromuscular monitoring in pediatrics reduced respiratory complications and produced cost savings versus no monitoring. According to Senzime, the researchers considered monitoring a dominant high-value strategy in pediatric anesthesia practice.

Why is Senzime's pediatric TetraGraph solution notable for investors in SNZZF?

Senzime’s pediatric monitoring solution is specifically designed with proprietary soft materials and has its own FDA 510(k) clearance. According to Senzime, it targets a demanding anesthesia segment where neuromuscular monitoring adoption remains lower than in adult care, suggesting room for growth.

How widespread is neuromuscular monitoring in pediatric anesthesia today?

Major studies cited by Senzime indicate that only about 16% of children receiving neuromuscular blocking drugs are adequately monitored. According to Senzime, lack of monitoring has been directly linked to higher rates of postoperative respiratory complications in pediatric patients.

How is Senzime expanding its pediatric anesthesia footprint beyond this new contract?

Senzime reports accelerating adoption of its technology in pediatric hospitals, with several important contracts recently secured across the U.S. and Europe. According to Senzime, these deals are supported by clinical and health economic data favoring quantitative neuromuscular monitoring in children.